Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

  title={Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats},
  author={Len Verbeke and Ricard Farr{\'e} and Jonel Trebicka and Mina Komuta and Tania A. Roskams and Sabine Klein and Ingrid Vander Elst and Petra Windmolders and Tim Vanuytsel and Frederik Nevens and Wim Laleman},
The farnesoid X receptor (FXR) is a nuclear bile acid receptor involved in bile acid homeostasis, hepatic and intestinal inflammation, liver fibrosis, and cardiovascular disease. We studied the effect of short‐term treatment with obeticholic acid (INT‐747), a potent selective FXR agonist, on intrahepatic hemodynamic dysfunction and signaling pathways in different rat models of cirrhotic portal hypertension (PHT). For this, thioacetamide (TAA)‐intoxicated and bile‐duct–ligated (BDL) rats were… 

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Preventative and therapeutic effects of FXR agonist obeticholic acid (OCA) inhibits hepatic inflammation in toxic cirrhotic rats resulting in decreased HSC activation and fibrosis.

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

The non-steroidal FXR agonist cilofexor decreased portal hypertension and reduced liver fibrosis in NASH rats and the combination with propranolol additionally reduced mesenteric hyperperfusion.

Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor‐dependent inhibition of hepatic stellate cell contraction

Investigation of mechanisms underlying DHA protection against chronic CCl4‐caused hepatic fibrosis and portal hypertension demonstrated that DHA attenuated portal hypertension in fibrotic rodents possibly by targeting HSC contraction via a FXR activation‐dependent mechanism.

Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats

Long-term administration of palosuran can decrease PP in cirrhosis, which results from decreased hepatic fibrosis and enhanced eNOS-dependent HSC vasodilatation, and in vitro UII/UT mRNA expression increases during HSC activation.

Obeticholic acid, a Farensoid‐X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

The observations still supported the conclusion that entecavir reduces hepatic events, and wellcharacterized cohort studies offer valuable insights into the benefits and limitations of antiviral therapy.

Obeticholic acid protects against carbon tetrachloride‐induced acute liver injury and inflammation

The Status of Bile Acids and Farnesoid X Receptor in Brain and Liver of Rats with Thioacetamide-Induced Acute Liver Failure

The results leave open the possibility that mobilization of the BA–FXR axis in the brain may not be necessarily pathognomonic to HE but may depend upon ALF-related confounding factors.

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis

Treatment with OCA effectively prevented chronic inflammation and liver fibrosis in WD-fed MC4R-KO mice with only marginal effect on body weight and hepatic steatosis, and demonstrates the anti-fibrotic effect of OCA in a murine model of NASH with obesity and insulin resistance, which suggests the clinical implication for human NASH.



Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.

Analysis of gene expression in livers from GW4064-treated cholestatic rats revealed decreased expression of bile acid biosynthetic genes and increased expression of genes involved in bile Acid transport, including the phospholipid flippase MDR2.

Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.

Treatment with nitroflurbiprofen, an NO-releasing cyclooxygenase inhibitor, improves portal hypertension without major adverse effects in thioacetamide-induced cirrhotic rats by attenuating intrahepatic vascular resistance, endothelial dysfunction, and hepatic hyperreactivity to vasoconstrictors.

A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis

Reduced intrahepatic endothelial nitric oxide synthase (eNOS) activity contributes to the pathogenesis of portal hypertension (PHT) associated with cirrhosis and in rats with biliary Cirrhosis, an endogenous NOS inhibitor, ADMA, may mediate decreased NOS activity.

Cyclooxygenase‐derived products modulate the increased intrahepatic resistance of cirrhotic rat livers

COX‐derived prostanoids, mainly TXA2, play a major role in regulating the response of cirrhotic livers to methoxamine and the mechanisms involved in its regulation are evaluated.

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

It is established that FXR ligands might represent a novel therapeutic option to treat liver fibrosis and that SHP binds JunD and inhibits DNA binding of adaptor protein (AP)-1 induced by thrombin.

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.

The data suggest that FXR loss significantly reduces fibrosis of the biliary type, but has no impact on non-cholestatic liver fibrosis.

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

FXR activation prevents chemically induced intestinal inflammation, with improvement of colitis symptoms, inhibition of epithelial permeability, and reduced goblet cell loss, and the findings provide a rationale to explore FXR agonists as a novel therapeutic strategy for IBD.

Role of bile acids and bile acid receptors in metabolic regulation.

Results suggest that modulation of FXR activity and BA metabolism may open new attractive pharmacological approaches for the treatment of the metabolic syndrome and type 2 diabetes.